1. A light emitting device package comprising:
a substrate with a recess;
a metal layer on the substrate; and
a light emitting device electrically connected to the metal layer and installed on the substrate,
wherein a side surface of the substrate has a convex structure, the convex structure having a first inclined surface and a second inclined surface contacting with each other,
wherein the metal layer comprises a plurality of protrusions, and
wherein the metal layer has a first metal portion in the recess and a second metal portion extending from the first metal portion and disposed on at least a portion of a bottom surface of the substrate
2. The light emitting device package according to claim 1, wherein a part of the second metal portion overlaps the first metal portion.
3. The light emitting device package according to claim 1, wherein the first inclined surface of the convex structure is substantially symmetrical to the first inclined surface of the convex structure with respect to a horizontal line.
4. The light emitting device package according to claim 1, wherein the first inclined surface has an acute angle with respect to the second inclined surface.
5. The light emitting device package according to claim 1, wherein at least one of the first and second inclined surfaces is flat.
6. The light emitting device package according to claim 1, wherein the first inclined surface contacts the bottom surface of the substrate, and
the first inclined surface has an obtuse angle with respect to the bottom surface of the substrate.
7. The light emitting device package according to claim 1, wherein the second inclined surface contacts a top surface of the substrate, and
the second inclined surface has an obtuse angle with respect to the top surface of the substrate.
8. The light emitting device package according to claim 1, wherein the convex structure is disposed along the side surface of the substrate.
9. The light emitting device package according to claim 1, wherein the convex structure protrudes from the side surface of the substrate toward a lateral direction
10. The light emitting device package according to claim 1, wherein the substrate has first and second portions having different thickness.
11. The light emitting device package according to claim 10, wherein the first portion has the recess and the second portion surrounds the first portion.
12. The light emitting device package according to claim 11, wherein a thickness of the light emitting device is smaller than a thickness of the first portion of the substrate.
13. The light emitting device package according to claim 1, wherein a depth of the recess is greater than a thickness of the light emitting device.
14. The light emitting device package according to claim 1, wherein the metal layer has a multiple structure.
15. The light emitting device package according to claim 1, wherein the side surface of the recess has an inclined surface.
16. The light emitting device package according to claim 15, wherein the metal layer is disposed on the inclined surface.
17. The light emitting device package according to claim 1, wherein the metal layer has a top surface and a bottom surface opposite to each other, at least one of the top surface and the bottom surface each having a roughness structure.
18. The light emitting device package according to claim 1, wherein the metal layer is disposed on an outer side surface of the substrate.
19. The light emitting device package according to claim 1, wherein the light emitting device is disposed on the first metal portion of the metal layer in the recess.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A kit of parts for gene delivery to a recipient cell in a host, using a gene delivery vehicle to which a humoral response can be raised, comprising a nucleic acid comprising a gene to be delivered to said recipient cell and further comprising a second composition of a second gene delivery vehicle essentially identical to said first gene delivery vehicle, but preferably lacking said gene to be delivered.
2. A kit of parts according to claim 1, wherein said second composition is a vaccine and wherein said first composition is a composition for gene therapy.
3. A kit of parts according to claim 2, wherein said vaccine is to be administered at a time before said gene therapy composition at a moment in time sufficient for the host to raise a neutralising humoral response to said second gene delivery vehicle.
4. A kit of parts according to any one of claims 1-3, wherein said second gene delivery vehicle comprises a nucleic acid encoding an indifferent protein.
5. A kit of parts according to any one of claims 1-4, wherein a gene delivery vehicle is of adenoviral origin.
6. A kit of parts according to any one of claims 2-5, wherein said gene therapy composition comprises a number of first gene delivery vehicles above the number that can be neutralised by a humoral response of said host.
7. A method for delivering a gene of interest to a recipient cell in a host using a gene delivery vehicle comprising a nucleic acid comprising said gene of interest, said method comprising administering to a host a vaccine composition comprising a gene delivery vehicle lacking said gene to be delivered, allowing for a neutralising humoral response to be raised by said host to said gene delivery vehicle lacking said gene to be delivered and administering a composition for gene therapy comprising essentially the same gene delivery vehicle having a nucleic acid comprising said gene to be delivered in an amount greater than the amount which can be neutralised by said humoral response.
8. A method for avoiding or diminishing liver toxicity in a host of a gene delivery composition upon administration, comprising administering to a host a vaccine composition comprising a gene delivery vehicle, preferably lacking said gene to be delivered, allowing for a neutralising humoral response to be raised by said host to said gene delivery vehicle lacking preferably said gene to be delivered and administering a composition for gene therapy comprising essentially the same gene delivery vehicle having a nucleic acid comprising said gene to be delivered in an amount greater than the amount which can be neutralised by said humoral response.
9. A method according to claim 7 or 8, wherein said gene delivery vehicle is of adenoviral origin.
10. A kit of parts according to any one of claims 1-6 in the preparation of a pharmaceutical for the use as a pharmaceutical.
11. Use of a kit of parts according to any one of claims 1-6 in the preparation of pharmaceutical for the treatment of diseases associated with uncontrolled proliferation of cells in a host, such as tumors or autoimmune diseases.
12. Use of a kit of parts according to any one of claims 1-6 in the preparation of a pharmaceutical for the treatment of diseases associated with genetic defects in a host.
13. A kit of parts according to any one of claims 1-6, wherein said gene of interest is interleukin-3.
14. A method for the preparation of a kit of parts according to anyone of claims 1-6, comprising preparing at least one gene delivery vehicle by inserting a gene of interest in a nucleic acid to be delivered to a host cell, packaging said nucleic acid in a vehicle capable of entering a host cell and bringing a resulting gene delivery vehicle in a medium suitable for administration to a host.
15. A method according to claim 14, wherein said nucleic acid is based on or derived from an adenovirus.
16. A method according to claim 14 or 15, wherein said vehicle comprises adenoviral structural proteins.
17. A method according to claim 16, wherein at least one vehicle comprises proteins from adenoviruses of different serotypes.
18. A method according to any one of claims 15-17, wherein said nucleic acid comprises at least one ITR and a packaging signal based on or derived from an adenovirus.
19. A method according to any one of claims 15-18, wherein said nucleic acid does not encode functional structural adenoviral proteins.
20. A method according to any one of claims 15-19, wherein said nucleic acid encodes E2A adenoviral gene product.
21. A method according to claim 20, wherein said E2A gene product is temperature sensitive.
22. A method according to any one of claims 14-21, wherein said packaging occurs in a packaging cell.
23. A method according to claim 22 wherein said packaging cell is derived from or based on a primary cell.
24. A method according to claim 23, wherein said cell is based on or derived from PER.C6.
25. A method according to any one of claims 15-18 wherein said nucleic acid comprising said gene of interest is produced by a recombination step from two adenoviral vectors.
26. A method according to any one of claims 15-25, wherein said adenovirus is an adenovirus serotype 5 or serotype 35.